Abstract
The results of the MA.32 trial, examining whether metformin improved breast cancer outcomes, were published in the Journal of the American Medical Association in May 2022.1 “Common diabetes drug not effective against early-stage breast cancer, landmark trial reveals,” read the associated online news headlines. Researchers entrenched in this field have eagerly awaited the results of the MA.32 trial for over a decade. To understand whether this trial is the end of the metformin in cancer story, herein, we summarize the trial and its results, explore its place in the context of previous studies, and its future, if any, in cancer studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
